global-alert
global messaging alerts

Expert Content LibraryIndustry Insights

A series of thought-provoking blogs covering topics such as, “How can heat be mitigated in the BFS packaging process?” and “What are the barrier properties of resin?”.

ApiJect Expert Industry Insights

  • June 29, 2022

    How Blow-Fill-Seal Delivers Operational Efficiencies and Aseptic Fill-Finish
    with Joe Wojcik, BFS Engineer

    Pharma expert, Joe Wojcik, discusses the technical factors and requirements that make BFS an “advanced aseptic process” for fill-finish, and why BFS has relatively low capital requirements

  • December 8, 2021

    What Have Been the Biggest Surprises with COVID-19?
    with Ed Kelley, PhD, Chief Global Health Officer

    The pandemic’s effects have been far more wide-reaching than many health officials expected, but COVID has also accelerated some positive trends.

  • November 9, 2021

    Advances in Sterile Liquids Packaging and Form Factors
    with Jon Burgess, Packaging Engineer

    Discussion  on packaging factors that have led to wider acceptance of Blow-Fill-Seal technology in the pharmaceutical industry.

  • November 2, 2021

    Strengths of Diversity in Pharma
    with Amy Stewart, Chief People Officer

    Companies are realizing that a strong commitment to DEI and ESG attracts employees. Word of mouth is very powerful. Companies want to do business with partners that are inclusive with positive values and environmental initiatives.

  • July 30, 2021

    The Surprising Strengths of Blow-Fill-Seal
    with Philip Leslie, Acting Head of Manufacturing

    Why does the FDA calls BFS an “advanced aseptic process”? How does BFS combine high-speed, economically efficient production with notable manufacturing flexibility? Respected industry veteran Philip Leslie explains “the basics of BFS.”

  • March 3, 2021

    The Heat Factor: Part 1 & 2:Why it Matters in Blow-Fill-Seal
    with Jeff Price, Consulting Principal BFS Engineer

    At ApiJect, our engineers have taken BFS filling enhancements even further by developing proprietary temperature control management methods that can potentially enable many temperature sensitive biologics and vaccines that are not possible on standard BFS lines.

Social media & sharing icons powered by UltimatelySocial
Twitter
YouTube
YouTube
LinkedIn
LinkedIn